Anti-Fibrinolytic Drugs - Worldwide

The revenue in the Anti-Fibrinolytic Drugs market worldwide is estimated to reach US$18.02bn in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 4.58%, leading to a market volume of US$22.55bn by 2029.
Among all countries, United States is expected to generate the highest revenue, amounting to US$9.86bn in 2024.
Despite being widely available worldwide, the usage of anti-fibrinolytic drugs varies significantly among countries due to differences in healthcare systems and prescribing practices.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs are used to prevent excessive bleeding in patients, especially during surgeries. The market for these drugs has been growing steadily in recent years due to increasing awareness about the benefits of these drugs.

Customer preferences: Customers prefer Anti-Fibrinolytic Drugs due to the benefits they offer in preventing excessive bleeding during surgery. Patients who are at risk of excessive bleeding due to medical conditions or medications also use these drugs. The preference for these drugs is expected to increase in the future due to the growing awareness about their benefits.

Trends in the market: The Anti-Fibrinolytic Drugs market is expected to grow in the Asia-Pacific region due to the increasing number of surgeries being performed in countries like India and China. The market is also expected to grow in North America and Europe due to the increasing geriatric population. These regions have a higher incidence of medical conditions that require surgeries, which in turn increases the demand for Anti-Fibrinolytic Drugs.

Local special circumstances: In India, the Anti-Fibrinolytic Drugs market is expected to grow due to the increasing number of surgeries being performed and the growing medical tourism industry. In China, the market is expected to grow due to the increasing investment in healthcare infrastructure and the growing number of hospitals. In the United States, the market is expected to grow due to the increasing geriatric population and the rising prevalence of medical conditions that require surgeries.

Underlying macroeconomic factors: The Anti-Fibrinolytic Drugs market is expected to grow due to the increasing investment in healthcare infrastructure in developing countries. The growing geriatric population in developed countries is also expected to drive the growth of the market. The increasing demand for minimally invasive surgeries is also expected to drive the growth of the market as these surgeries require the use of Anti-Fibrinolytic Drugs. Additionally, the increasing awareness about the benefits of these drugs is expected to drive the growth of the market in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.